

# **Prediction of Threonine-Tyrosine Kinase Receptor**−**Ligand Unbinding Kinetics with Multiscale Milestoning and Metadynamics**

Lane W. [Votapka,](https://pubs.acs.org/action/doSearch?field1=Contrib&text1="Lane+W.+Votapka"&field2=AllField&text2=&publication=&accessType=allContent&Earliest=&ref=pdf) [Anupam](https://pubs.acs.org/action/doSearch?field1=Contrib&text1="Anupam+Anand+Ojha"&field2=AllField&text2=&publication=&accessType=allContent&Earliest=&ref=pdf) Anand Ojha, [Naoya](https://pubs.acs.org/action/doSearch?field1=Contrib&text1="Naoya+Asada"&field2=AllField&text2=&publication=&accessType=allContent&Earliest=&ref=pdf) Asada, and [Rommie](https://pubs.acs.org/action/doSearch?field1=Contrib&text1="Rommie+E.+Amaro"&field2=AllField&text2=&publication=&accessType=allContent&Earliest=&ref=pdf) E. Amaro[\\*](#page-3-0)

**Cite This:** *J. Phys. Chem. Lett.* 2024, 15, [10473−10478](https://pubs.acs.org/action/showCitFormats?doi=10.1021/acs.jpclett.4c02332&ref=pdf) **Read [Online](https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332?ref=pdf) ACCESS [Metrics](https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332?goto=articleMetrics&ref=pdf) & More ARTICLE Article [Recommendations](https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332?goto=recommendations&?ref=pdf) Supporting [Information](https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332?goto=supporting-info&ref=pdf)** 

ABSTRACT: Accurately describing protein−ligand binding and unbinding kinetics remains challenging. Computational calculations are difficult and costly, while experimental measurements often lack molecular detail and can be unobtainable. Here, we extend our multiscale milestoning method, Simulation-Enabled Estimation of Kinetics Rates (SEEKR), with metadynamics molecular dynamics simulations to yield accurate small molecule drug residence times. Using the pharmaceutically relevant threonine-tyrosine kinase (TTK) and eight long-residence-time (tens of seconds to hours) inhibitors, we demonstrate accurate prediction of absolute and rankordered ligand residence times and free energies of binding.

**B** iological systems involve a vast array of complex<br>intermolecular interactions. The binding and unbinding<br>of a ligand-recentor pair can be described by 1) thermody of a ligand−receptor pair can be described by 1) thermodynamics, which considers equilibrium quantities like the free energy of binding ( $\Delta G_{bind}$ ) and the equilibrium constant (K<sub>D</sub>), and 2) kinetics, which considers time-dependent quantities like the rate constant of binding  $(k_{on})$ , the rate constant of unbinding ( $k_{off}$ ), and the residence time  $(1/k_{off})$  $(1/k_{off})$  $(1/k_{off})$ .<sup>1</sup> Knowledge of these quantities is desirable for predicting a drug's efficacy<sup>[2](#page-4-0)−[5](#page-4-0)</sup> and optimizing specificity in drug discovery.<sup>6</sup> While experimental measurements of binding/unbinding kinetics and thermodynamics are possible, accurate and efficient computational predictions remain attractive. Simulation-Enabled Estimation of Kinetics Rates (SEEKR) is a multiscale, simulation-based, enhanced sampling method used to characterize the kinetics and thermodynamics of a variety of binding/unbinding systems.  $\real^{9-15}$  $\real^{9-15}$  $\real^{9-15}$  $\real^{9-15}$  $\real^{9-15}$ 

Metadynamics (metaD) is an enhanced sampling method that estimates the free energy landscapes of complicated systems.<sup>[16](#page-4-0)−[20](#page-4-0)</sup> It accelerates the exploration of the free energy landscape by introducing a collective variable (CV)-based history-dependent bias potential that evolves over time, searching for new metastable states during MD simula-tions.<sup>17,[21](#page-4-0)</sup> Previously, SEEKR used steered molecular dynamics (SMD) for generating starting structures. In this work, we use the GPU-accelerated well-tempered metaD implementation within SEEKR. Threonine-tyrosine kinase (TTK), also known as monopolar spindle 1 (MPS1), is frequently overexpressed in highly proliferative cancers, making it a promising drug target for human breast cancer.<sup>[22](#page-4-0)</sup> A recent study revealed that residence time, rather than potency  $(IC_{50})$ , has a stronger correlation with antiproliferative activity. $23$  Improving the



kinetic properties of TTK inhibitors is essential, but the binding and unbinding mechanism is still unclear.

We ran SEEKR on eight TTK systems with experimental residence times available [\(Figure](#page-1-0) 1). Details of the computational methods, benchmarks, and simulation costs are in the Supporting [Information](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf) (SI). SEEKR requires generating starting structures for simulations within the milestoning framework. Previously, this was done with SMD, which uses a harmonic restraint moving at a constant velocity along the CV to sample starting structures. In this study, we explore the use of metaD, which gradually fills the energy landscape with Gaussian boosts, allowing the ligand to gradually sample steep energy landscape portions. This comparison of initial sampling approaches within SEEKR - using SMD versus metaD - can be found in [Figure](#page-2-0) 2 (Exact numerical values can be found in [Tables](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf) S1 and S2).

Results for  $k_{off}$  show that SEEKR2 with metaD produced the best results [\(Figure](#page-2-0) 2A; medium blue). In contrast, SMD ([Figure](#page-2-0) 2A; light blue) produces suboptimal results. Predictions within a single order of magnitude of the experiment were found for all TTK system  $k_{on}$  estimates except TC-Mps1−12 ([Figure](#page-2-0) 2B). We examined the reasons for the large deviation and believe it is due to the reparametrized partial charges of the ligand in the bound state using QMrebind, which caused the charges to become

Received: August 8, 2024 Revised: September 27, 2024 Accepted: October 1, 2024 Published: October 11, 2024





© <sup>2024</sup> The Authors. Published by American Chemical Society **<sup>10473</sup>**

<span id="page-1-0"></span>

Figure 1. TTK structure, prominent features, and ligands. In the center, the TTK protein is shown as a translucent white surface, taken from the Xray crystal structure 5NAD<sup>23</sup>.

highly polarized. The  $k_{on}$  calculation depends on an accurate description of the unbound state, where molecular charges are likely to be less polarized. By applying the bound state QMrebind charges to the unbound state of compound TC-Mps1−12, as done in this study, a large desolvation penalty is incurred, significantly slowing the binding rate. Preliminary studies (data not shown) support this hypothesis, though further careful analysis is needed to fully validate it. The free energies of binding were computed by using the equation  $\Delta G_{bind}$  = kBT·ln(k<sub>off</sub>/k<sub>on</sub>) [\(Figure](#page-2-0) 2C). Clearly, the biggest deviation in TC-Mps1−12 was caused by the highly incorrect  $k_{on}$  obtained for that system. In addition, the free energies of binding were computed by the difference in free energies of the MMVT anchors between the bound state and the predefined 'escaped' state at the mouth of the binding site ([Figure](#page-2-0) 2D). Definitions of the binding sites are provided in the [SI](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf). While a large systematic bias is caused by the missing solvation energy

of a true separation between ligand and receptor, the trend is very good - generating an almost perfect ranking.

SEEKR obtains a Kendall's tau of 0.64 and a mean absolute  $log_{10}$  error of 1.2 for ranking of absolute unbinding kinetics using metaD, and a Kendall's tau of 0.50 with a mean absolute log<sub>10</sub> error of 3.1 for the same with SMD and QMrebind. Values for  $k_{on}$  and  $\Delta G_{bind}$  were also computed for the TTK systems and are reported in [Figures](#page-2-0) 2B, [2C](#page-2-0), and [2D](#page-2-0). The Kendall's tau for this series of  $k_{on}$  values was found to be −0.18, and the mean absolute log<sub>10</sub> of the error was computed to be 0.66; for this series of  $\Delta G_{bind}$  values (computed from  $k_B T \cdot ln(k_{off}/k_{on}))$ , the Kendall's tau was 0.71, with a mean absolute error of 1.9 kcal/mol. When the  $\Delta G_{bind}$  values were computed from the relative free energies of Markovian milestoning with Voronoi tesselations (MMVT) anchors, it gives Kendall's tau of 0.93 and a mean absolute error of 2.5

<span id="page-2-0"></span>

Figure 2. TTK  $k_{off}$  rate constants (A),  $k_{on}$  rate constants (B), and  $\Delta G_{bind}$  using:  $k_B T \cdot ln(k_{off}/k_{on})$  (C) and the difference in free energies of the MMVT anchors between bound and 'escaped' states (D) for known inhibitors.



Figure 3. Cartoon schematic comparing exploration of correct and incorrect unbinding pathways using SMD (panel A) and metaD (panel B). In both panels, the green arrow represents the correct unbinding path, while the incorrect unbinding paths are red arrow(s).

kcal/mol. (Exact numerical values for  $\mathbf{k}_{\rm off}$  values can be found in [Table](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf) S1,  $k_{on}$  and  $\Delta G_{bind}$  values can be found in Table S2).

In addition to the method of kinetics prediction, the choice and preparation of system structure files for the receptor and ligand are very important,<sup>24−[27](#page-4-0)</sup> including the selection of high-

<span id="page-3-0"></span>quality experimentally determined structures, ensuring physical realism (matching experimental conditions like temperature, pressure, ion concentrations, and pH), carefully considering protonation states of ligands and receptor residues, and performing adequate minimization and equilibration to ensure that the system is modeled near a thermodynamic equilibrium state. The choice of force field parameters for SEEKR calculations is also critical. We use the QMrebind method<sup>13</sup> to redefine the partial charges of the ligand in the bound state, which works well for the TTK system, particularly affecting the partial charges on a tert-butyl side group [\(Figure](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf) S1) although, as we mentioned before, this likely negatively impacted the  $k_{on}$  estimate for TC-Mps1−12. Other force field parameters, such as ligand torsions, may also benefit from refinement - a topic we do not address here. All the partial charges, both before and after using QMrebind to reparametrize them, can be found in [Table](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf) S3.

Challenges arise when modeling halogens $^{28}$  $^{28}$  $^{28}$  due to the 'sigma hole', producing a positive partial charge opposite the covalent bond with chlorine, bromine, or iodine atoms. In particular, inaccuracies have been observed when the halogen interacts with Lewis bases. However, fluorine's small sigma hole can be adequately described with a point charge,  $29$  as shown by the successful application of SEEKR to the TTK 'BAY 1217389' and 'NMS-P715' systems, which contain many fluorines.

After system preparation, choosing the CV, and providing force field parameters, the SEEKR MMVT algorithm populates each Voronoi cell with starting structures to run simulations and gather milestoning times and statistics. The HIDR tool within SeekrTools ([https://github.com/seekrcentral/](https://github.com/seekrcentral/seekrtools.git) [seekrtools.git](https://github.com/seekrcentral/seekrtools.git)) facilitates this by exploring the entire reaction coordinate span and saving potential starting structures. We found that metaD provides superior starting structures compared to other methods. Previously, SMD was commonly used for generating starting structures for SEEKR. However, more complex ligands with large, flexible structures lead to artificial tearing and unfolding of the protein. SMD sometimes pushed the ligand along the wrong unbinding pathway or through the binding site's interior surface, resulting in inaccurate SEEKR kinetics predictions ([Figure](#page-2-0) 3A).

While adverse effects of SMD can sometimes be mitigated by carefully reselecting the atoms defining the binding site, alternative sampling algorithms like metaD allow the ligand to backtrack and explore multiple exit pathways [\(Figure](#page-2-0) 3B). MetaD works well for this purpose, unlike SMD, which constrains the ligand to a particular CV value and can push it through the binding site's interior surface if stuck. As shown in [Figure](#page-2-0) 3A, SMD might explore the correct unbinding path, but if the ligand gets pushed along the incorrect unbinding path, up against an interior surface of the binding site, the inability of SMD to 'back up' causes the ligand to get pushed through the interior surface. In contrast, in [Figure](#page-2-0) 3B, metaD can also sample the correct unbinding path, but if the incorrect unbinding path is explored, the surface of the binding site will stop the ligand, and the metaD sampling algorithm will allow the ligand to backtrack.

However, using metaD to generate starting structures has its challenges. If the Gaussian height is too large, it can disrupt the molecular system, affecting the accuracy of the SEEKR calculation (data not shown). Conversely, generating starting structures can be time-consuming and resource-intensive if the Gaussian heights are too small. The choice of CV is also

nontrivial and can complicate practical use, especially for lessstudied receptors.[30](#page-5-0)−[32](#page-5-0)

Convergence is important for SEEKR calculations to determine if additional sampling is necessary or if an incorrect physical description impacts accuracy. Convergence plots in [Figure](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf) S2 show that metaD starting structures converge better than SMD, likely because metaD sample structures with lower energy closer to the true unbinding pathway.

In this work, we expand SEEKR's capabilities and demonstrate its success in estimating binding and unbinding kinetics for the TTK system and eight small molecules with residence times from seconds to hours. The combined use of metaD for initial structure generation and quantum-mechanically reparametrized ligands significantly improves SEEKR calculations. We believe this protocol, which integrates SEEKR and metaD to predict binding and unbinding kinetics and thermodynamics, will be broadly useful for various ligand− receptor systems, provided each system is described with sufficient physical accuracy. However, challenges remain for systems with heavy halogens due to sigma holes, systems where protonation states or partial charges change significantly along the unbinding pathway, or systems lacking suitable molecular mechanics force fields. Additionally, increasingly large or complex ligands may pose significant challenges. Efforts to address these and other unforeseen issues are ongoing and will be resolved in future research iterations. SEEKR2 open-source software is available at GitHub: [https://github.com/](https://github.com/seekrcentral/seekr2.git) [seekrcentral/seekr2.git](https://github.com/seekrcentral/seekr2.git), and SeekrTools, which runs metaD and SMD, at <https://github.com/seekrcentral/seekrtools.git>. Files to prepare systems and inputs for SEEKR calculations can be found at [https://github.com/seekrcentral/seekr2\\_systems/](https://github.com/seekrcentral/seekr2_systems/tree/master/systems/TTK) [tree/master/systems/TTK.](https://github.com/seekrcentral/seekr2_systems/tree/master/systems/TTK) Data for the systems in this study can be obtained from [10.6075/J0571C7G.](https://doi.org/10.6075/J0571C7G)

# ■ **ASSOCIATED CONTENT**

#### $\bullet$  Supporting Information

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332](https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332?goto=supporting-info).

Computational Methods Benchmarking and Simulation Costs; Table S1 - Unbinding kinetics for TTK systems; Table S2 - Binding kinetics and free energies for TTK systems; Figure S1: Reparametrization of charges using QMrebind on compound TC-Mps1-12; Table S3 - TTK system ligand charge reparametrization from AM1BCC charges to QMrebind charges; Figure S2 - Convergence of k<sub>off</sub> for TTK Systems; Table S4 - TTK system binding site definitions; Table S5 - TTK system anchor radii ([PDF](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_001.pdf))

Transparent Peer Review report available [\(PDF](https://pubs.acs.org/doi/suppl/10.1021/acs.jpclett.4c02332/suppl_file/jz4c02332_si_002.pdf))

## ■ **AUTHOR INFORMATION**

# **Corresponding Author**

Rommie E. Amaro − *Department of Molecular Biology, University of California San Diego, La Jolla, California 92093, United States;* [orcid.org/0000-0002-9275-9553](https://orcid.org/0000-0002-9275-9553); Email: [ramaro@ucsd.edu](mailto:ramaro@ucsd.edu)

### **Authors**

Lane W. Votapka − *Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, United States;* [orcid.org/0000-0002-](https://orcid.org/0000-0002-0865-5867) [0865-5867](https://orcid.org/0000-0002-0865-5867)

- <span id="page-4-0"></span>Anupam Anand Ojha − *Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, United States; Center for Computational Biology and Center for Computational Mathematics, Flatiron Institute, New York 10010, United States;* [orcid.org/](https://orcid.org/0000-0001-6588-3092) [0000-0001-6588-3092](https://orcid.org/0000-0001-6588-3092)
- Naoya Asada − *Laboratory for Medicinal Chemistry Research, Shionogi & CO. Ltd, Osaka 541-0045, Japan*

Complete contact information is available at: [https://pubs.acs.org/10.1021/acs.jpclett.4c02332](https://pubs.acs.org/doi/10.1021/acs.jpclett.4c02332?ref=pdf)

### **Notes**

The authors declare no competing financial interest.

■ **ACKNOWLEDGMENTS**<br>The authors thank Steffen Wolf, University of Freiburg, for his insightful and valuable discussions. The authors express their gratitude to Shiksha Dutta and Mac Kevin E. Braza for their assistance with the figures. Thanks to Jeff Wagner for helpful discussions about force field parametrization as well as assistance with testing, continuous integration, and GitHub. A. A. O. acknowledges the support of the Merkin Fellowship from the University of California San Diego. All simulations were performed using the Popeye computing cluster at the San Diego Supercomputing Center (SDSC) and the Delta supercomputing system at the National Center for Supercomputing Applications (NCSA), University of Illinois Urbana−Champaign. The authors acknowledge support from NSF Advanced Cyberinfrastructure Coordination Ecosystem: Services and Support (ACCESS) CHE060063. The authors thank the Laboratory for Medicinal Chemistry Research, Shionogi and CO. Ltd, Osaka, Japan, for their collaborative efforts and contributions.

■ **REFERENCES**<br>
(1) Bernetti, M.; Masetti, M.; Rocchia, W.; Cavalli, A. [Kinetics](https://doi.org/10.1146/annurev-physchem-042018-052340) of Drug Binding and [Residence](https://doi.org/10.1146/annurev-physchem-042018-052340) Time. *Annu. Rev. Phys. Chem.* 2019, *70* (1), 143−171.

(2) Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug−[Target](https://doi.org/10.1038/nrd2082) Residence Time and Its Implications for Lead [Optimization.](https://doi.org/10.1038/nrd2082) *Nat. Rev. Drug Discov.* 2006, *5* (9), 730−739.

(3) Copeland, R. A. The [Drug-Target](https://doi.org/10.1038/nrd.2015.18) Residence Time Model: A 10- Year [Retrospective.](https://doi.org/10.1038/nrd.2015.18) *Nat. Rev. Drug Discov.* 2016, *15* (2), 87−95.

(4) Huggins, D. J.; Sherman, W.; Tidor, B. Rational [Approaches](https://doi.org/10.1021/jm2010332?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) to [Improving](https://doi.org/10.1021/jm2010332?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Selectivity in Drug Design. *J. Med. Chem.* 2012, *55* (4), 1424−1444.

(5) Fang, Y. [Ligand-Receptor](https://doi.org/10.1517/17460441.2012.715631) Interaction Platforms and Their [Applications](https://doi.org/10.1517/17460441.2012.715631) for Drug Discovery. *Expert Opin. Drug Discov.* 2012, *7* (10), 969−988.

(6) Tang, Z.; Roberts, C. C.; Chang, C. A. [Understanding](https://doi.org/10.2741/4527) Ligand-Receptor [Non-Covalent](https://doi.org/10.2741/4527) Binding Kinetics Using Molecular Modeling. *Front. Biosci. Landmark Ed.* 2017, *22*, 960−981.

(7) Liu, W.; Jiang, J.; Lin, Y.; You, Q.; Wang, L. [Insight](https://doi.org/10.1021/acs.jmedchem.2c00682?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) into [Thermodynamic](https://doi.org/10.1021/acs.jmedchem.2c00682?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) and Kinetic Profiles in Small-Molecule Optimiza[tion.](https://doi.org/10.1021/acs.jmedchem.2c00682?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) *J. Med. Chem.* 2022, *65* (16), 10809−10847.

(8) Tonge, P. J. Drug−Target Kinetics in Drug [Discovery.](https://doi.org/10.1021/acschemneuro.7b00185?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) *ACS Chem. Neurosci.* 2018, *9* (1), 29−39.

(9) Votapka, L. W.; Amaro, R. E. Multiscale [Estimation](https://doi.org/10.1371/journal.pcbi.1004381) of Binding Kinetics Using Brownian [Dynamics,](https://doi.org/10.1371/journal.pcbi.1004381) Molecular Dynamics and [Milestoning.](https://doi.org/10.1371/journal.pcbi.1004381) *PLOS Comput. Biol.* 2015, *11* (10), e1004381.

(10) Votapka, L. W.; Jagger, B. R.; Heyneman, A. L.; Amaro, R. E. SEEKR: [Simulation](https://doi.org/10.1021/acs.jpcb.6b09388?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Enabled Estimation of Kinetic Rates, A [Computational](https://doi.org/10.1021/acs.jpcb.6b09388?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Tool to Estimate Molecular Kinetics and Its Application to Trypsin−[Benzamidine](https://doi.org/10.1021/acs.jpcb.6b09388?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Binding. *J. Phys. Chem. B* 2017, *121* (15), 3597−3606.

(11) Jagger, B. R.; Lee, C. T.; Amaro, R. E. [Quantitative](https://doi.org/10.1021/acs.jpclett.8b02047?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Ranking of Ligand Binding Kinetics with a Multiscale [Milestoning](https://doi.org/10.1021/acs.jpclett.8b02047?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Simulation [Approach.](https://doi.org/10.1021/acs.jpclett.8b02047?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) *J. Phys. Chem. Lett.* 2018, *9* (17), 4941−4948.

(12) Jagger, B. R.; Ojha, A. A.; Amaro, R. E[.Predicting](https://doi.org/10.1021/acs.jctc.0c00495?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Ligand Binding Kinetics Using a Markovian [Milestoning](https://doi.org/10.1021/acs.jctc.0c00495?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) with Voronoi [Tessellations](https://doi.org/10.1021/acs.jctc.0c00495?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Multiscale Approach *J. Chem. Theory Comput.* 2020, *16* (8), 5348.

(13) Ojha, A. A.; Votapka, L. W.; Amaro, R. E. [QMrebind:](https://doi.org/10.1039/D3SC04195F) Incorporating Quantum Mechanical Force Field [Reparameterization](https://doi.org/10.1039/D3SC04195F) at the Ligand Binding Site for Improved [Drug-Target](https://doi.org/10.1039/D3SC04195F) Kinetics through Milestoning [Simulations.](https://doi.org/10.1039/D3SC04195F) *Chem. Sci.* 2023, *14* (45), 13159− 13175.

(14) Ojha, A. A.; Srivastava, A.; Votapka, L. W.; Amaro, R. E. Selectivity and Ranking of [Tight-Binding](https://doi.org/10.1021/acs.jcim.2c01589?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) JAK-STAT Inhibitors Using Markovian Milestoning with Voronoi [Tessellations.](https://doi.org/10.1021/acs.jcim.2c01589?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) *J. Chem. Inf. Model.* 2023, *63* (8), 2469−2482.

(15) Votapka, L. W.; Stokely, A. M.; Ojha, A. A.; Amaro, R. E. SEEKR2: Versatile Multiscale [Milestoning](https://doi.org/10.1021/acs.jcim.2c00501?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Utilizing the OpenMM [Molecular](https://doi.org/10.1021/acs.jcim.2c00501?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Dynamics Engine. *J. Chem. Inf. Model.* 2022, *62* (13), 3253−3262.

(16) Barducci, A.; Bonomi, M.; Parrinello, M. [Metadynamics.](https://doi.org/10.1002/wcms.31) *WIREs Comput. Mol. Sci.* 2011, *1* (5), 826−843.

(17) Bussi, G.; Laio, A. Using [Metadynamics](https://doi.org/10.1038/s42254-020-0153-0) to Explore Complex [Free-Energy](https://doi.org/10.1038/s42254-020-0153-0) Landscapes. *Nat. Rev. Phys.* 2020, *2* (4), 200−212.

(18) Tiwary, P.; Parrinello, M. From [Metadynamics](https://doi.org/10.1103/PhysRevLett.111.230602) to Dynamics. *Phys. Rev. Lett.* 2013, *111* (23), 230602.

(19) Laio, A.; Gervasio, F. L. [Metadynamics:](https://doi.org/10.1088/0034-4885/71/12/126601) A Method to Simulate Rare Events and [Reconstruct](https://doi.org/10.1088/0034-4885/71/12/126601) the Free Energy in Biophysics. *Chemistry and Material Science. Rep. Prog. Phys.* 2008, *71* (12), 126601.

(20) Ensing, B.; De Vivo, M.; Liu, Z.; Moore, P.; Klein, M. L. [Metadynamics](https://doi.org/10.1021/ar040198i?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) as a Tool for Exploring Free Energy Landscapes of Chemical [Reactions.](https://doi.org/10.1021/ar040198i?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) *Acc. Chem. Res.* 2006, *39* (2), 73−81.

(21) Laio, A.; Parrinello, M. Escaping [Free-Energy](https://doi.org/10.1073/pnas.202427399) Minima. *Proc. Natl. Acad. Sci. U. S. A.* 2002, *99* (20), 12562−12566.

(22) Schmidt, M.; Budirahardja, Y.; Klompmaker, R.; Medema, R. H. Ablation of the Spindle Assembly [Checkpoint](https://doi.org/10.1038/sj.embor.7400483) by a Compound [Targeting](https://doi.org/10.1038/sj.embor.7400483) Mps1. *EMBO Rep* 2005, *6* (9), 866−872.

(23) Uitdehaag, J. C. M.; de Man, J.; Willemsen-Seegers, N.; Prinsen, M. B. W.; Libouban, M. A. A.; Sterrenburg, J. G.; de Wit, J. J. P.; de Vetter, J. R. F.; de Roos, J. A. D. M.; Buijsman, R. C.; Zaman, G. J. R. Target Residence [Time-Guided](https://doi.org/10.1016/j.jmb.2017.05.014) Optimization on TTK Kinase Results in Inhibitors with Potent [Anti-Proliferative](https://doi.org/10.1016/j.jmb.2017.05.014) Activity. *J. Mol. Biol.* 2017, *429* (14), 2211−2230.

(24) Gathiaka, S.; Liu, S.; Chiu, M.; Yang, H.; Stuckey, J. A.; Kang, Y. N.; Delproposto, J.; Kubish, G.; Dunbar, J. B.; Carlson, H. A.; Burley, S. K.; Walters, W. P.; Amaro, R. E.; Feher, V. A.; Gilson, M. K. D3R Grand Challenge 2015: [Evaluation](https://doi.org/10.1007/s10822-016-9946-8) of Protein−Ligand Pose and Affinity [Predictions.](https://doi.org/10.1007/s10822-016-9946-8) *J. Comput. Aided Mol. Des.* 2016, *30* (9), 651− 668.

(25) Gaieb, Z.; Liu, S.; Gathiaka, S.; Chiu, M.; Yang, H.; Shao, C.; Feher, V. A.; Walters, W. P.; Kuhn, B.; Rudolph, M. G.; Burley, S. K.; Gilson, M. K.; Amaro, R. E. D3R Grand Challenge 2: Blind [Prediction](https://doi.org/10.1007/s10822-017-0088-4) of Protein−Ligand Poses, Affinity [Rankings,](https://doi.org/10.1007/s10822-017-0088-4) and Relative Binding Free [Energies.](https://doi.org/10.1007/s10822-017-0088-4) *J. Comput. Aided Mol. Des.* 2018, *32* (1), 1−20.

(26) Gaieb, Z.; Parks, C. D.; Chiu, M.; Yang, H.; Shao, C.; Walters, W. P.; Lambert, M. H.; Nevins, N.; Bembenek, S. D.; Ameriks, M. K.; Mirzadegan, T.; Burley, S. K.; Amaro, R. E.; Gilson, M. K. D3R [Grand](https://doi.org/10.1007/s10822-018-0180-4) Challenge 3: Blind [Prediction](https://doi.org/10.1007/s10822-018-0180-4) of Protein−Ligand Poses and Affinity [Rankings.](https://doi.org/10.1007/s10822-018-0180-4) *J. Comput. Aided Mol. Des.* 2019, *33* (1), 1−18.

(27) Parks, C. D.; Gaieb, Z.; Chiu, M.; Yang, H.; Shao, C.; Walters, W. P.; Jansen, J. M.; McGaughey, G.; Lewis, R. A.; Bembenek, S. D.; Ameriks, M. K.; Mirzadegan, T.; Burley, S. K.; Amaro, R. E.; Gilson, M. K. D3R Grand Challenge 4: Blind [Prediction](https://doi.org/10.1007/s10822-020-00289-y) of Protein−Ligand Poses, Affinity [Rankings,](https://doi.org/10.1007/s10822-020-00289-y) and Relative Binding Free Energies. *J. Comput. Aided Mol. Des.* 2020, *34* (2), 99−119.

(28) Ibrahim, M. A. A. Molecular [Mechanical](https://doi.org/10.1002/jcc.21836) Study of Halogen Bonding in Drug [Discovery.](https://doi.org/10.1002/jcc.21836) *J. Comput. Chem.* 2011, *32* (12), 2564− 2574.

<span id="page-5-0"></span>(29) Wehrhan, L.; Keller, B. G. [Fluorinated](https://doi.org/10.1021/acs.jpcb.4c01493?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Protein−Ligand Complexes: A [Computational](https://doi.org/10.1021/acs.jpcb.4c01493?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as) Perspective. *J. Phys. Chem. B* 2024, *128* (25), 5925−5934.

(30) Hayward, S.; Go, N. Collective Variable [Description](https://doi.org/10.1146/annurev.pc.46.100195.001255) of Native Protein [Dynamics.](https://doi.org/10.1146/annurev.pc.46.100195.001255) *Annu. Rev. Phys. Chem.* 1995, *46*, 223−250.

(31) Berendsen, H. J.; Hayward, S. [Collective](https://doi.org/10.1016/S0959-440X(00)00061-0) Protein Dynamics in Relation to [Function.](https://doi.org/10.1016/S0959-440X(00)00061-0) *Curr. Opin. Struct. Biol.* 2000, *10* (2), 165−169.

(32) Bhakat, S. [Collective](https://doi.org/10.1039/D2RA03660F) Variable Discovery in the Age of Machine Learning: Reality, Hype and [Everything](https://doi.org/10.1039/D2RA03660F) in Between. *RSC Adv.* 2022, *12* (38), 25010−25024.